PHA-Exch> UN report finds gaps in access to essential medicines

[Claudio Schuftan]

From: Vern Weitzel <vern.weitzel at gmail.com>
crossposted from: "[health-vn discussion group]" <health-vn at cairo.anu.edu.au>,



Delivering on the Global Partnerships for Achieving the Millennium
Development 8

Arabic [pdf 1.56Mb]
<http://www.who.int/entity/medicines/mdg/MDG8ArabicWeb.pdf>     |
Chinese [pdf 2.02Mb]
<http://www.who.int/entity/medicines/mdg/MDG8ChineseWeb.pdf>
English [pdf 1.67Mb]
<http://www.who.int/entity/medicines/mdg/MDG8EnglishWeb.pdf>   | French
[pdf 1.42Mb] <http://www.who.int/entity/medicines/mdg/MDG8FrenchWeb.pdf>

Russian [pdf 1.45Mb]
<http://www.who.int/entity/medicines/mdg/MDG8RussianWeb.pdf>  | Spanish
[pdf 1.56Mb]
<http://www.who.int/entity/medicines/mdg/MDG8SpanishWeb.pdf>

"…..The UN report Delivering on the Global Partnerships for Achieving
the Millennium Development Goals highlights the existence of large
gaps in the availability of medicines in both the public and private
sectors, as well as a wide variation in prices which render essential
medicines unaffordable to poor people.

Launched on September 4th by the UN Secretary-General, the report
describes progress towards achieving MDG 8 (Develop a global
partnership for development) and its related targets in the areas of
essential medicines, official development assistance, trade, external
debt and technology.

MDG 8, Target 8.E: In cooperation with pharmaceutical companies,
provide access to affordable essential medicines in developing
countries was measured using nine indicators for measuring access to
medicines using data collected by WHO and its partners. The report
found that in the public sector, generic medicines are only available
in 34.9% of facilities, and on average cost 250% more than the
international reference price. In the private sector, those same
medicines are available in 63.2% of facilities, but cost on average
about 650% more than the international reference price. While policies
that promote access such as generic substitution are in place in many
countries, additional national and international efforts are required
to improve the availability and affordability of medicines. …"

Content

Executive summary
Official development assistance.
Market access (trade)
Debt sustainability.
Access to affordable essential medicines
Access to new technologies
Public-private partnerships or privatization?
The need to strengthen the global partnership for access to new
technology . . . ."
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://phm.phmovement.org/pipermail/phm-exchange-phmovement.org/attachments/20080906/e61cf6b5/attachment-0001.html>